Approximately 3.6 million people in Europe and the USA suffer from recurrent auto-immune-mediated infl ammation of the gastrointestinal tract. Infl ammatory bowel disease (IBD) comprises two entities: Crohn ' s disease (CD) and ulcerative colitis (UC). In the past, experimental studies (mostly in mice) have improved our understanding of the aberrant interaction between the intestinal microbiota and the immune system. The perturbed immune reaction in IBD exhibits specifi c and individual cytokine responses that distinguish the two variants. A deep understanding of the immunological response at every stage of the chronic disease enables the provision of modern, effi cient medical treatment that takes into account individual immunological and genetic characteristics. In this review, the current knowledge on the epidemiology and genetics of IBD is summarized, and new pathogenetic insights as well as promising future therapeutic options are described.
Introduction
Approximately 1.4 million people in the USA and 2.2 million in Europe suffer from infl ammatory bowel disease (IBD) (1) that is comprised of two distinct entities:
Crohn ' s disease (CD) and ulcerative colitis (UC) (2) , both of which are recurrent infl ammatory diseases. However, UC is restricted to the colon, only affects the colonic mucosa and does not spread into the colonic wall. Depending on the anatomical extent along the colon, UC patients can be classifi ed as suffering from proctitis, left-sided colitis or pancolitis, when the whole colon is affected. The infl ammatory pattern of CD differs signifi cantly from that of UC. In contrast to UC, immune cell infi ltration and tissue damage in CD spreads throughout the whole colonic wall and may even lead to fi stula. CD is not restricted to the colon and can affect the whole gastrointestinal tract (3) . Both forms of IBD carry a risk for colon cancer if the chronic infl ammatory reaction is not adequately suppressed. In a large metaanalysis, the prevalence of colorectal cancer in UC patients was 3.7 % ; the incidence was correlated with the duration of the disease, with cumulative probabilities of 2 % after 10 years and 18 % after 30 years (4) . A recent meta-analysis in CD patients calculated that their risk for colorectal cancer was approximately doubled compared with that of an age-matched standard population, but was only moderate compared with that of UC patients. In addition, CD patients are also at an approximate 19-fold risk for developing small bowel cancer (5) .
Genetic factors
IBD was demonstrated to be dependent on multiple genetic factors, and an aberrant immune response to environmental agents probably plays a role in disease pathogenesis in genetically susceptible individuals (2) . Recent reports on immigrants from India and Bangladesh to the UK demonstrated that genetic characteristics play a crucial role in the development of CD (6) . Studies of twins have always been popular when trying to differentiate between environmental agents and inherited factors in the pathogenesis of IBD (7) . The phenotypic concordance in monozygotic twins with CD was 50 % -75 % with an approximately 800-fold increased relative risk for developing CD (2) ; however, concordance was only 10 % -20 % for twins with UC (2) . As reported in several genome-wide association studies (8, 9) , there is a considerable overlap in genetic risk factors between both forms of IBD. Different gene loci have been identifi ed as being associated with an increased risk for UC, e.g., genes that are related to regulatory pathways (10) , epithelial cell function and protein degradation (11) .
Specific gene loci associated with CD include autophagy genes (12, 13) (e.g., ATG16L1 ), intelectins (14) and nucleotide oligomerization domain (NOD)-like receptors (15) . Autophagy is the process of degradation of cellular contents that are encapsulated in the autophagosome, and finally delivered to the lysosome. The crucial role of ATG16L1 in autophagic processes was demonstrated by knockdown of the respective gene in small interfering RNA. Other reports showed a pivotal role of ATG16L1 *300A (*300A symbolizes a non-synonymous amino acid change at position 300 of alanine to threonine) in bacterial handling (9) . Moreover, Atg16L1-knockout mice died during the neonatal period which revealed a fundamental role of this gene in survival during neonatal starvation (9) . Intriguingly, hematopoietic cells derived from Atg16L1-/-mice exhibited increased interleukin (IL)-1 β and IL-18 levels together with an increased susceptibility to dextran sodium sulphate (DSS) colitis, which were reversed by treatment with antibodies against IL-1 β and IL-18 (16) . One in five patients with CD in western countries exhibits a mutation in the NOD2 gene; this was not an important factor in Indians, and indicates a cohort-specific genetic susceptibility (6) . In the past few decades, UC has tended to be more common than CD in the majority of western countries, but, in the past few years, this ratio has been reversed in many countries (17) . It should be noted that gene pools do not change that rapidly, but environmental factors do, emphasizing the importance of environmental antigens in the pathogenesis of IBD (17) . Moreover, the role of several hundreds of common single nucleotide polymorphisms of minor biological impact is not yet clear and these may be responsible for sporadic cases of IBD (18) .
The intestinal barrier
An intact intestinal barrier is obligatory to prevent spontaneous overwhelming inflammation due to a microbialimmune interaction. However, the epithelial monolayer, which has its tight junctions that build a barrier between the lumen and the intestinal wall, does not fully protect the intestines from invasion by environmental antigens and microorganisms (19) . Small breaks in the epithelial surface and in specialized areas within the epithelium (follicle-associated epithelium) that overlie the organized lymphoid tissues of the intestinal wall allow direct communication of the two " compartments " (20) . However, an intact immune system is capable of destroying a few invaders through phagocytosis without provoking exaggerated cytokine production (21) . Thus, it is believed that states in which commensal bacteria either enter in increased numbers or persist in the lamina propria may lead to repeated, excessive immune responses which may result in Crohn ' s-like disease. Indeed, children with congenital defects of the innate immune system that result in impaired elimination of commensal bacteria frequently develop Crohn ' s-like disease (22, 23) . Similarly, mice with epithelial defects in the small intestine also develop Crohn ' s-like disease, spontaneously (24) . In summary, these data provide strong evidence that the key initial steps in the development of mucosal inflammation are antigen invasion into the lamina propria, incomplete degradation of these antigens and finally excessive T-cell activation. In this context, CD4 + Foxp3 + regulatory T-cells play a major role in the maintenance of intestinal homeostasis. Through the release of IL-10 and tumor growth factor (TGF)-β , they not only control T-cell but also B-cell function, which makes them another interesting intrinsic therapeutic target (25) .
Microbiota and mucosal immunity
The largest internal surface of the human body, the gastrointestinal tract, is constantly exposed to a vast number of exogenous antigens and harbors a myriad of commensal bacteria that direct mucosal immunity. About 1014 microorganisms of more than 1000 species reside in the gastrointestinal tract (26, 27) , and about 90 % of all species are Gram-negative and Gram-positive bacteria (28) . The microbiotic flora is not only important for digestive processes or vitamin synthesis, but also directs mucosal and even systemic immune functions (29, 30 ) . An interesting example is the influence of Bacteroides thetaiotaomicron on innate immune cell capabilities. It directly activates Toll-like receptors on Paneth cells within the intestinal epithelium thereby increasing antimicrobial peptide expression (31) . With regard to the adaptive immune system function of T-cell receptor (TCR) α β intraepithelial lymphocytes (32) , T regulatory cells (33) and the differentiation of Th17 cells were shown to be influenced by certain commensal bacteria. Cytophaga-flavobacterbacteroides bacteria induced Th17 cell differentiation via a TGF-β -dependent pathway; the absence of bacteria led to a shift in T-cell patterns towards the population of regulatory T-cells in the lamina propria (34) . These observations led to the interesting question of whether the lack of any intestinal flora results in local or systemic immune deficits. Indeed, germ-free mice showed enhanced auto-inflammatory responses due to inadequate T regulatory cell function (33, 35) . In summary, commensal bacteria have profound effects on innate and adaptive immune functions with important implications in human IBD. Accordingly, probiotics and antibiotics are effective therapeutics in UC rather than in CD (36) .
Targeting dendritic cell and macrophage function
The gastrointestinal tract and the skin are the major sites of exposure to microbial and parasitic pathogens (37) . Thus, a balanced immune system in these organs is fundamental for survival. Foreign antigens and pathogens have to be eliminated, but collateral damage has to be minimized. This challenge has to be met by the cells of the innate immune system, which comprise dendritic cells (DCs) and macrophages and reside in the gut-associated lymphoid tissue but are also scattered throughout the lamina propria (38) . These mononuclear phagocytes are also key elements in the course of adaptive immune reactions. Because macrophages and DCs exert distinct functions, individual targeting may have signifi cant therapeutic potential (38) . For instance, macrophage-specifi c deletion of the transcription factor, peroxisome proliferator-activated receptor-γ , signifi cantly worsened experimental colitis by impairing regulatory T-cell function and increasing the population of cytotoxic CD8 + T-cells (39) .
Cytokines in IBD
Previous studies have shown the upregulation of many pro-infl ammatory and immune-regulatory cytokines in the mucosa of IBD patients, and distinct cytokine patterns in both UC and CD have been demonstrated in various studies (40) . The levels of many lipid mediators of infl ammation, such as prostaglandins, leukotrienes, as well as platelet-activating factor (41) , chemokines (40) and several pro-infl ammatory cytokines, were elevated in the infl amed mucosa of IBD patients. The major pro-infl ammatory cytokine of Th1-mediated immune responses, IL-12, was identifi ed in a model of experimental colitis that resembles human CD [trinitrobenzene sulphonic acid (TNBS) colitis], for which treatment with anti-IL-12p40 was very effi cient (42) . Similarly, patients with CD exhibited increased tissue levels of IL-12 in the lamina propria compared with controls (43) . This discovery led to the development of a human anti-IL-12p40 antibody for the treatment of CD patients. This therapy had a similar effi cacy to that of anti-tumor necrosis factor (TNF)-α (see below) and, moreover, could induce remission in patients with anti-TNF-α resistance (44, 45) . The surprising observation that anti-IL12p40 exacerbated a mouse model of human UC (oxazolone colitis) infl uenced the concept of two distinct pathways of T-helper cell-mediated forms of colitis. In line with the hypothesis of a Th2-driven model of UC, anti-IL-4 treatment prevented the disease. Oxazolone colitis is also distinguished by a major involvement of natural killer T (NKT)-cells and IL-13 (43) (Figure 1 ). Consequently, IL-13 blockage through IL-13R2-Fc antibodies or deletion of NKT cells led to considerable improvement. Supporting this concept, CD1-defi cient mice that exhibit defi cits in antigen presentation to NKT cells as well as J α 281-/-mice that lack invariant TCRs on NKT cells did not develop oxazolone colitis (43) . Treatment with anti-TNF-α antibody and recombinant human IL-10 were benefi cial in the majority of CD patients in various trials, refl ecting the pivotal role of TNF-α in the pathogenesis The two major models of chemically induced colitis that resemble human IBD. TNBS and oxazolone are both believed to haptenize colonic antigens; by co-application of ethanol, epithelial integrity is disrupted and the antigen complex can be presented to innate immune cells which results in an exaggerated immune response. Similarly to CD, TNBS colitis is directed by a Th1/Th17 phenotype, whereas, oxazolone colitis produces a Th2-like pattern of cytokine expression and NKT cells are essential. Regulatory T-cells are responsible for the dampening of an overwhelming immune response and may ultimately help to resolve the acute disease.
of CD and the regulatory power of IL-10 which selectively down-regulates pro-infl ammatory T-cell populations in the colonic mucosa (40) . Enhanced levels of Th1-type cytokines were found in mucosal samples from anti-TNF-α -responsive patients (46) . However, in this cohort, only about 30 % of patients responded to anti-IL-10 therapy (40) . These data suggest individual differences in the types of infl ammation in IBD. Targeting these cytokines in addition to TNF-α is a promising approach for the future treatment of IBD. Mucosal biopsies in combination with blood tests could identify the individual cytokine pattern of infl ammation of a patient and may lead to personalized therapies in the future.
Gene therapy
Our growing understanding of the combined actions of the immune system, the discovery of specifi c pro-and anti-infl ammatory effects of certain cytokines, transcription factors or cell-cycle regulatory proteins have raised the question of whether it is feasible to deliver certain in situ therapeutic strategies to minimize systemic impact. Studies in cell lines and animal models showed that topically applied liposomal and viral vector systems suffi ciently transduced information into the gut wall (47 -51) . With regard to colitis, this approach was shown to be effective because local administration of an adenovirus expressing IL-18 antisense mRNA attenuated T-cell-mediated colitis. Moreover, TGF-β gene transfer was effective in preventing and attenuating experimental murine colitis (52) . Bactofection is the process of delivering plasmid DNA to target tissue using bacteria. Oral bactofection in vivo was shown to attenuate DSS colitis in mice. Plasmids with genes encoding for Cu-Zn superoxide dismutase and a mutant of monocyte chemoattractant protein-1 carried by attenuated Salmonella typhimurium had anti-oxidative and anti-infl ammatory effects, respectively (53) . In another study, nanoparticles were loaded with small interfering RNA against the cell-cycle regulatory molecule CyD1, which is over-expressed under infl ammatory conditions. The use of antibodies against β (7) integrins selectively silenced CyD1 in mononuclear leukocyte subsets in vivo (54) . This approach protected mice from DSS colitis by effectively suppressing leukocyte proliferation and pro-infl ammatory cytokine expression derived from Th1-type T-helper cells. Further studies are currently being conducted to identify whether recombinant probiotics that express therapeutic genes would be useful IBD therapeutics.
Colitis -a disease of the sensory nervous system ?
Crucial neuro-immune interactions have been demonstrated in several infl ammatory diseases, including colitis. Specialized sensory neurons -so called nociceptors -physiologically sense noxious stimuli and, upon activation, convey these signals to the central nervous system which ultimately leads to the sensation of pain. However, the peptidergic subpopulation of these nerve fi bers releases neuropeptides, as a result of antidromic activation of peripheral nerve terminals (55) . The two major " sensory " neuropeptides -calcitonin gene-related peptide (CGRP) and substance P (SP) -have been shown to be the critical link between the sensory nervous and the immune systems (55, 56) . Pharmacological blockage of the SP receptor neurokinin (NK)1 was benefi cial in TNBS and DSS colitis (57, 58) . Recent studies on SP, CGRP and double knockout mice confi rmed the pro-infl ammatory effects of SP in experimental colitis and demonstrated the protective effects of CGRP (56, 59) , which had been suggested previously (60, 61) . Several in vitro studies showed that the effects of SP and CGRP on the immune system are very complex and are more extensive than those of classical neurogenic infl ammation, which comprises vasodilatation and plasma extravasation. SP and CGRP exert direct effects on different types of immune cells by changing their cytokine patterns and chemotactic properties (62, 63) .
The ion channels TRPV1 (vanilloid) and TRPA1 (ankyrin) are members of the transient receptor potential (TRP) family that control the release of CGRP and SP from sensory neurons. Previous studies reported controversial data with regard to the role of TRPV1 in experimental colitis. Pharmacological inhibition or null mutation of the TRPV1 receptor was protective (64, 65) or had no effect (56, 66) in TNBS and DSS colitis, and TRPV1-defi cient mice challenged with dinitrobenzene sulphonic acid (DNBS) even showed increased susceptibility to colitis (67) . The involvement of the TRPA1 receptor in infl ammation was fi rst described in a model of asthma (68) . Defi ciencies in chemically and allergen-induced pulmonary neuropeptide release in TRPA1-/-mice was suggested to be responsible for the impaired infl ammatory response. Accordingly, we recently identifi ed the crucial role of the TRPA1 receptor channel in mediating TNBS colitis (56) . TNBS was shown to activate TRPA1 on sensory neurons by releasing massive amounts of the pro-infl ammatory neuropeptide SP. Mice lacking TRPA1 were protected from TNBS colitis; however, DSS colitis was also attenuated in TRPA1-/-mice and treatment of sick mice led to considerable improvements. Because DSS did not activate neurons, attenuation of DSS colitis by inhibition/null mutation of TRPA1 suggested that the activation/ sensitization of TRPA1 occurred during infl ammation which led to an increased release of the SP, thus maintaining the infl ammatory process in DSS colitis (Figure 2 ). Possible endogenous candidates for TRPA1 receptor sensitization were metabolites of oxidative stress, such as 4-hydroxynonenal, which induced TRPA1-dependent colonic SP release, and the colonic tissue levels of which were increased in DSS and TNBS colitis (56) . However, data on the role of TRPA1 in human IBD are lacking, and the ultimate molecular mechanisms by which SP and CGRP affect immune cells in colitis have yet to be elucidated. However, these exciting new insights may lead to a novel therapeutic avenue and blockers of ion channels in sensory neurons or antagonists of " sensory " neuropeptides may be another promising approach in the medical treatment of IBD. 
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